Klotho and Follistatin combination plasmid gene therapy
undiscloseddrug program · high · Tue Dec 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Investigate safety and efficacy of combined Klotho and Follistatin gene therapy in healthy adult volunteers, including cognitive and health benefits.
Combination Klotho and Follistatin gene therapy delivered via nonviral plasmid in a human clinical study.
ClinicalTrials.gov record for Safety and Efficacy of Klotho and Follistatin Gene Therapy published on 2025-12-16.
Klotho plasmid gene therapy
undiscloseddrug program · high · Mon Oct 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Assess safety, efficacy, cognitive benefits, and health benefits of injectable Klotho gene therapy in healthy adult volunteers.
Injectable non-viral plasmid gene therapy for Klotho administered in a human clinical study.
ClinicalTrials.gov record for Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans published on 2025-10-06.
Follistatin plasmid gene therapy
phase 1drug program · high · Thu Aug 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Increase lean mass, lower body fat percentage, improve well-being, assess metabolic and epigenetic changes, and evaluate safety and effects of injectable human FST344 follistatin expression.
Injectable non-viral plasmid gene therapy containing the human FST344 gene, with DEXA scans, metabolic and epigenetic blood panels, adverse-event monitoring, and circulating follistatin measurement before and after administration.
Phase I clinical trial sponsored by Minicircle at the Global Alliance for Regenerative Medicine clinical research site in Roatan, Honduras, published on 2022-08-18.
A site-listed 2021 publication reports that follistatin plasmid therapy extended mouse lifespan by 32.5%; human trial outcomes are not provided in the supplied material.
Follistatin therapy
undiscloseddrug program · high
Support lean muscle, vitality, body composition, and epigenetic age in the context of longevity, performance, and wellness.
Investigational non-viral, non-heritable plasmid gene therapy administered as a subcutaneous treatment.
Presented on the site as Minicircle's Follistatin therapy offered through partner clinics.
Anecdotal testimonials describe improved gym performance, recovery, and muscle gain after receiving Follistatin therapy, but no formal publication or trial result is supplied.
Follistatin Therapy
undiscloseddrug program · high
Support lean muscle, vitality, body composition, recovery, and epigenetic age using a follistatin-based gene therapy.
Non-viral, non-heritable plasmid gene therapy administered subcutaneously through partner clinics.
Presented on Minicircle's site as an available investigational therapy offered through independent international partner clinics.
Supplied site material includes user testimonials describing muscle gain, easier gym performance, improved recovery, and a simple procedure, but no controlled clinical efficacy results are provided.
Klotho therapy
exploratorydrug program · medium
Develop a Klotho-focused gene therapy program for longevity or wellness applications.
Not specified beyond inclusion in Minicircle's plasmid gene therapy offering context.
Listed on the site as coming in 2026.
Klotho Therapy
exploratorydrug program · medium
Develop a Klotho-focused plasmid gene therapy as part of Minicircle's longevity and wellness therapy offering.
Plasmid gene therapy; supplied material does not provide further protocol details.
Listed by Minicircle as coming in 2026.
Minicircle non-viral plasmid gene therapy platform
undisclosedplatform · high
Offer investigational non-viral, non-heritable plasmid gene therapies for longevity, performance, and wellness through independent international partner clinics.
Non-viral plasmid gene therapy platform delivered through subcutaneous treatment via partner clinics.
Platform described publicly as available through independent international partner clinics.
Non-viral plasmid gene therapy platform
exploratoryplatform · medium
Develop and offer non-viral, non-heritable plasmid gene therapies for longevity, performance, wellness, body composition, and related human enhancement goals through independent international partner clinics.
Non-viral plasmid gene therapy platform administered outside the United States under local regulatory frameworks through partner clinics.
Minicircle lists global clinic locations including GARM sites in Paradise Island, Bahamas and Roatan, Honduras, plus Xtend Optimal Health Center in Panama City, Panama.
Plasmid Gene Therapy Platform
undisclosedplatform · high
Develop non-viral, non-heritable plasmid gene therapies for longevity, performance, wellness, and human enhancement through partner clinics.
Non-viral plasmid gene therapy platform delivered through investigational therapies under medical supervision at independent international partner clinics.
Minicircle states it partners with licensed clinics to offer investigational gene therapies and lists active clinic locations in the Bahamas, Honduras, and Panama.
